PHARMACOTHERAPEUTIC APPROACHES IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS: A COMPREHENSIVE REVIEW

[1]ALUGANI MANISH GOUD, [2]RATHOD KIRAN, [3]REPAKA PRANAY,

[4]NAJAM UDDIN SIDDIQUI, [5] JANGA AKSHAY, [6] Dr. CHANDRASEKHARA RAO BARU.

[1]Student, [2]student, [3]student, [4]student, [5]student, [6]principal.

[1]Pharmacy practice,

[1]Chilkur Balaji College of Pharmacy, Hyderabad, India

Abstract: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterised by insulin resistance and progressive beta-cell dysfunction, affecting over 537 million adults globally. This review comprehensively examines the pharmacotherapeutic strategies available for T2DM management, encompassing oral agents (metformin, sulfonylureas, SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, thiazolidinediones, alpha-glucosidase inhibitors) and injectable therapies (insulin, GLP-1 RAs). Evidence-based guidelines from the American Diabetes Association (ADA) emphasise individualised, patient-centred care with cardiovascular and renal risk stratification guiding drug selection. Emerging therapies including dual GIP/GLP-1 agonists and oral insulin formulations are shaping the future landscape. The clinical pharmacist plays an indispensable role in optimising therapy, managing adverse effects, and improving adherence. Key challenges include medication affordability, hypoglycaemia risk, and polypharmacy. This review synthesises current evidence to guide evidence-based clinical decision-making in T2DM pharmacotherapy.

IndexTerms - Type 2 diabetes mellitus; antidiabetic drugs; metformin; SGLT2 inhibitors; GLP-1 receptor agonists; insulin; ADA guidelines; clinical pharmacist

1. INTRODUCTION

Type 2 diabetes mellitus (T2DM) represents one of the most pressing global public health challenges of the 21st century. It is a chronic, progressive metabolic disorder defined by sustained hyperglycaemia resulting from a combination of impaired insulin secretion and peripheral insulin resistance. The International Diabetes Federation (IDF) estimates that 537 million adults (20–79 years) were living with diabetes in 2021, projected to rise to 783 million by 2045. [1] Unlike type 1 diabetes, T2DM is largely preventable and manageable through lifestyle modification and pharmacotherapy. Early and sustained glycaemic control is critical to prevent microvascular complications (retinopathy, nephropathy, neuropathy) and macrovascular events (myocardial infarction, stroke). Pharmacotherapy has expanded dramatically over the past two decades, from the traditional biguanide metformin to novel agents offering cardioprotective and renoprotective benefits beyond glucose lowering. [2] This review provides a comprehensive overview of current pharmacotherapeutic strategies, guided by evidence-based frameworks, to support optimal clinical practice.

2. Epidemiology

T2DM constitutes approximately 90–95% of all diabetes cases worldwide. [1] Prevalence is highest in the Western Pacific and Middle East regions, and is rapidly increasing in South Asia due to urbanisation, sedentary lifestyles, and dietary shifts. In India alone, approximately 77 million individuals are living with diabetes, making it the second-largest diabetes population globally. [3] The condition disproportionately affects adults over 45 years; however, an alarming rise is observed among younger populations. T2DM is associated with significant economic burden — estimated at USD 966 billion globally in 2021 — and is a leading cause of blindness, kidney failure, and lower-limb amputation. [1] Ethnicity, family history, obesity (BMI ≥30 kg/m²), physical inactivity, and gestational diabetes history are established risk factors. Early pharmacological intervention alongside lifestyle modification forms the cornerstone of management.

3. Pathophysiology

The "ominous octet" described by DeFronzo encapsulates the multifactorial pathophysiology of T2DM. [4] Central mechanisms include: (i) skeletal muscle insulin resistance reducing glucose uptake; (ii) impaired first-phase insulin secretion from pancreatic β-cells; (iii) increased hepatic glucose production via gluconeogenesis; (iv) adipocyte lipolysis generating excess free fatty acids; (v) α-cell hypersecretion of glucagon; (vi) renal tubular glucose reabsorption via SGLT2 overactivity; (vii) incretin deficiency or resistance (reduced GLP-1 and GIP effect); and (viii) central nervous system dysregulation of appetite and glucose homeostasis. [4,5] Progressive β-cell loss over time — attributed to glucotoxicity, lipotoxicity, and oxidative stress — necessitates escalating pharmacotherapy. Understanding these pathways directly informs the mechanism-based selection of antidiabetic agents.

4. Goals of Therapy

The primary goals of T2DM pharmacotherapy extend beyond glycaemic control. The ADA Standards of Medical Care in Diabetes recommend an HbA1c target of <7.0% for most non-pregnant adults, with individualised targets (6.5–8.5%) based on patient factors including age, hypoglycaemia risk, comorbidities, and life expectancy. [6] Additional therapeutic targets include blood pressure <130/80 mmHg, LDL cholesterol <70 mg/dL in high-risk patients, weight management, and prevention of cardiovascular and renal events. [6] Emerging frameworks emphasise cardiorenal protection as co-equal goals alongside glycaemic control, fundamentally reshaping treatment algorithms. Patient quality of life, medication tolerability, cost, and treatment complexity are equally integral to goal-setting in shared decision-making.

5. Classification of Antidiabetic Drugs

5.1 Oral Antidiabetic Agents

The major classes of oral antidiabetic drugs (OADs) are summarised in Table 1 below.

Table 1. Classification and Key Features of Oral Antidiabetic Agents

Drug Class	Examples	Mechanism	HbA1c Reduction	Key Advantage
Biguanides	Metformin	↓ Hepatic glucose output; ↑ insulin sensitivity	1.0–2.0%	First-line; weight neutral; low cost
Sulfonylureas (SU)	Glibenclamide, Glimepiride, Gliclazide	Stimulates insulin secretion (closes KATP channel)	1.0–2.0%	Rapid efficacy; low cost
DPP-4 Inhibitors	Sitagliptin, Saxagliptin, Vildagliptin	Inhibits DPP-4 → ↑ GLP-1 & GIP activity	0.5–0.8%	Weight neutral; safe in elderly
SGLT2 Inhibitors	Empagliflozin, Dapagliflozin, Canagliflozin	Blocks renal SGLT2 → glucosuria	0.5–1.0%	CV/renal protection; weight ↓
Thiazolidinediones (TZD)	Pioglitazone	PPARγ agonist → ↑ insulin sensitivity	0.5–1.4%	NASH benefit; durable
α-Glucosidase Inhibitors	Acarbose, Voglibose	Delays carbohydrate absorption	0.5–0.8%	Post-prandial glucose control
Meglitinides	Repaglinide, Nateglinide	Short-acting insulin secretagogues	0.5–1.5%	Flexible meal dosing

5.2 Injectable Antidiabetic Agents

Injectable therapies include subcutaneous insulin formulations and GLP-1 receptor agonists (GLP-1 RAs). Insulin remains the most potent glucose-lowering agent, with unlimited efficacy and no absolute contraindications except hypersensitivity. [7] GLP-1 RAs (e.g., semaglutide, liraglutide, dulaglutide) offer the added benefit of weight reduction (2–5 kg) and cardiovascular risk reduction. [8] Weekly injectable formulations (once-weekly semaglutide) have improved patient adherence significantly. Table 2 summarises injectable options.

Table 2. Injectable Antidiabetic Agents

Agent	Class	Dosing	HbA1c Reduction	Special Feature
Liraglutide	GLP-1 RA	Once daily SC	1.0–1.5%	CV benefit (LEADER trial)
Semaglutide	GLP-1 RA	Once weekly SC / Oral	1.5–2.0%	Superior weight loss
Dulaglutide	GLP-1 RA	Once weekly SC	1.0–1.5%	Pre-filled pen; easy use
Insulin Glargine	Basal insulin	Once daily SC	1.5–2.5%	Low hypoglycemia risk
Insulin Degludec	Ultra-long basal	Once daily SC	1.5–2.5%	Ultra-long action (42h)
Insulin Aspart	Rapid-acting	With meals SC	Variable	Flexible mealtime dosing
Tirzepatide	GIP/GLP-1 dual RA	Once weekly SC	2.0–2.5%	Superior glycaemic + weight control

6. Mechanisms of Action

Metformin activates AMP-activated protein kinase (AMPK) in hepatocytes, suppressing gluconeogenesis and improving peripheral insulin sensitivity without stimulating insulin secretion, thus carrying no hypoglycaemia risk as monotherapy. [9] Sulfonylureas bind the SUR1 subunit of the pancreatic KATP channel, depolarising the β-cell membrane and triggering insulin exocytosis; this mechanism is glucose-independent, explaining hypoglycaemia risk. [10] SGLT2 inhibitors block the sodium-glucose co-transporter 2 in the proximal tubule, causing renal glucosuria and natriuresis, with secondary benefits including reduced preload/afterload and intraglomerular pressure. [11] GLP-1 RAs act on GLP-1 receptors in the pancreas, brain, heart, and gut — stimulating glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. [8] DPP-4 inhibitors prevent degradation of endogenous incretins (GLP-1, GIP), amplifying their glucose-lowering actions. [12] Pioglitazone, a PPARγ agonist, transcriptionally regulates genes governing adipocyte differentiation and fatty acid storage, redistributing lipids away from visceral depots, improving whole-body insulin sensitivity.

7. Evidence-Based Guidelines

The ADA Standards of Medical Care in Diabetes (2024) recommend metformin as the preferred first-line agent for most patients with T2DM, initiated alongside lifestyle modification at diagnosis. [6] However, in patients with established atherosclerotic cardiovascular disease (ASCVD), heart failure, or chronic kidney disease (CKD), an SGLT2 inhibitor or GLP-1 RA with proven cardiovascular benefit is recommended regardless of HbA1c or metformin use. [6] The EMPA-REG OUTCOME trial demonstrated a 38% relative risk reduction in cardiovascular death with empagliflozin in patients with T2DM and ASCVD. [13] The LEADER trial showed liraglutide reduced major adverse cardiovascular events (MACE) by 13% versus placebo. [14] CREDENCE and DAPA-CKD trials established canagliflozin and dapagliflozin, respectively, as nephroprotective agents, reducing the risk of end-stage kidney disease by approximately 30–34%. [15,16] The European Association for the Study of Diabetes (EASD) similarly endorses a cardiorenal risk-stratified treatment algorithm. [17]

8. Individualised and Combination Therapy

Modern T2DM management advocates for a patient-centred, individualised approach considering HbA1c levels, comorbidities (ASCVD, HF, CKD), body weight, hypoglycaemia risk, cost, and patient preference. [6] Combination therapy is frequently required as the disease progresses due to the natural decline in β-cell function. [18] The most evidence-supported combinations include: metformin + SGLT2 inhibitor (complementary mechanisms, additive weight and BP reduction); metformin + GLP-1 RA (superior HbA1c and weight reduction); metformin + DPP-4 inhibitor (weight-neutral, well-tolerated); and basal insulin + GLP-1 RA (reduced hypoglycaemia vs. basal-bolus regimens). [6,18] Triple therapy or early insulin initiation may be warranted in patients presenting with HbA1c >10% or symptomatic hyperglycaemia. Fixed-dose combinations (FDCs) improve adherence and reduce pill burden. [19]

9. Adverse Effects and Drug Interactions

9.1 Adverse Effects

Each drug class carries a distinct adverse effect profile. Metformin commonly causes gastrointestinal effects (nausea, diarrhoea) in up to 20% of patients, reduced by slow titration or extended-release formulations; rare lactic acidosis risk occurs primarily in severe renal impairment (eGFR <30 mL/min/1.73m²). [9] Sulfonylureas carry significant hypoglycaemia risk and modest weight gain (~2 kg); gliclazide and glimepiride have lower hypoglycaemia risk than glibenclamide. [10] SGLT2 inhibitors are associated with urogenital tract infections (2–4-fold increase), Fournier's gangrene (rare), euglycaemic DKA (especially in type 1 or perioperative settings), and lower-limb amputations (canagliflozin). [11] GLP-1 RAs cause predominantly gastrointestinal adverse effects (nausea, vomiting, diarrhoea), typically transient; thyroid C-cell tumours noted in rodent studies necessitate caution in patients with personal/family history of MEN2 or medullary thyroid cancer. [8] Pioglitazone causes fluid retention, weight gain, increased fracture risk in women, and a possible association with bladder cancer with long-term use. [20] DPP-4 inhibitors are generally well-tolerated; saxagliptin and alogliptin showed increased heart failure hospitalisation in the SAVOR-TIMI 53 and EXAMINE trials, respectively. [12]

9.2 Drug Interactions

Clinically significant drug interactions in T2DM management include: metformin with iodinated contrast media (hold 48h peri-procedure); fluoroquinolones + sulfonylureas (increased hypoglycaemia risk via CYP2C9 inhibition); rifampicin + sulfonylureas/repaglinide (reduced efficacy via CYP3A4/CYP2C9 induction); [21] beta-blockers masking hypoglycaemia symptoms and impairing counter-regulatory response; alcohol potentiating insulin and sulfonylurea-induced hypoglycaemia; corticosteroids antagonising glycaemic control requiring dose adjustment; diuretics exacerbating SGLT2 inhibitor-related volume depletion. [21] Careful medication reconciliation by clinical pharmacists is essential to mitigate these interactions.

10. Role of the Clinical Pharmacist

Clinical pharmacists are indispensable members of the multidisciplinary diabetes care team. Their roles encompass: (i) medication therapy management (MTM) including drug selection, dosing, and de-prescribing; (ii) patient education on injection technique, self-monitoring of blood glucose (SMBG), hypoglycaemia recognition and management; (iii) adherence counselling and addressing medication-related problems; (iv) monitoring for adverse effects and drug interactions; (v) cardiorenal risk stratification and evidence-based drug selection; and (vi) formulary management and cost-effectiveness analysis. [22] Studies demonstrate that pharmacist-led MTM services reduce HbA1c by an additional 0.5–1.5% compared to usual care. [23] The ADA recognises pharmacists as key members of the diabetes care team. [6] In community settings, pharmacists serve as accessible frontline providers for diabetes screening, point-of-care testing, and immunisation services, significantly impacting population-level outcomes.

11. Recent Advances

Several transformative advances have reshaped T2DM pharmacotherapy in recent years:

- Tirzepatide (Mounjaro®), a first-in-class dual GIP/GLP-1 receptor agonist, demonstrated HbA1c reductions of 2.0–2.3% and weight loss of 8–12 kg in the SURPASS trials, surpassing semaglutide in head-to-head comparisons.

[24]

- Oral semaglutide (Rybelsus®) became the first oral GLP-1 RA approved, enabling non-injectable delivery with comparable cardiovascular outcomes (PIONEER-6 trial).

[25]

- Retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, is in Phase 3 trials demonstrating unprecedented weight loss (~24%) in early data.

[26]

- SGLT1/SGLT2 dual inhibitors (e.g., sotagliflozin) offer additional post-prandial glucose control via gut SGLT1 inhibition.

[27]

- Closed-loop insulin delivery systems (artificial pancreas) integrating continuous glucose monitors (CGMs) with automated insulin pumps are showing promising results in T2DM.

[28]

- Stem cell therapy and islet transplantation remain investigational but represent potential curative strategies for selected patients.

12. Challenges in T2DM Pharmacotherapy

Despite therapeutic advances, several challenges persist. Medication affordability remains a critical barrier — newer agents such as SGLT2 inhibitors and GLP-1 RAs, despite proven cardiorenal benefits, are prohibitively expensive in low- and middle-income countries (LMICs). [29] Therapeutic inertia — the delayed initiation or intensification of therapy despite suboptimal control — is prevalent in clinical practice, contributing to prolonged hyperglycaemia and complications. [30] Polypharmacy in elderly patients with T2DM and multiple comorbidities increases the risk of adverse events and non-adherence. Hypoglycaemia — particularly with insulin and sulfonylureas — remains a major safety concern associated with increased cardiovascular events and dementia risk. [31] Additionally, comorbid depression (prevalent in ~15–25% of T2DM patients) adversely impacts self-management behaviours and glycaemic outcomes. Patient health literacy, cultural barriers, and food insecurity further complicate pharmacotherapeutic management globally.

13. Future Perspectives

The future of T2DM pharmacotherapy is characterised by precision medicine, novel mechanisms, and digital integration. Pharmacogenomics-guided prescribing — utilising genetic variants in CYP2C9, SLC22A1, and TCF7L2 — holds promise for predicting drug response and individualising therapy. Novel targets under investigation include glucagon receptor antagonists, G-protein coupled receptor 119 (GPR119) agonists, and mitochondria-targeted insulin sensitisers. [26] Gut microbiome modulation via faecal transplantation and targeted prebiotics is emerging as an adjunctive approach. Personalised digital health tools — including smartphone-based glucose tracking, AI-driven insulin dosing algorithms, and telehealth-integrated diabetes management platforms — are expanding access and optimising outcomes. [32] The anticipated approval of retatrutide and oral SGLT2 inhibitor combinations will further expand therapeutic options. Ultimately, a cure remains the goal, with ongoing research into beta-cell regeneration, immunotherapy for preserved beta-cell function, and metabolic surgery offering broader eligibility.

14. Conclusion

T2DM pharmacotherapy has undergone a paradigm shift from solely glucose-centric management to a holistic, cardiorenal risk-based, patient-centred approach. Metformin remains the cornerstone of first-line therapy, but agents with proven cardiovascular and renal benefits — particularly SGLT2 inhibitors and GLP-1 receptor agonists — have become integral to the treatment algorithm for high-risk patients. Newer therapies such as tirzepatide and oral semaglutide offer superior efficacy and patient convenience. The clinical pharmacist plays a pivotal role in ensuring evidence-based, safe, and cost-effective pharmacotherapy. Addressing challenges of affordability, therapeutic inertia, and polypharmacy is essential for translating therapeutic advances into improved population-level outcomes. Continued investment in research, digital health tools, and global access to innovative therapies is imperative to effectively combat the T2DM epidemic.

REFERENCES

1. International Diabetes Federation. IDF Diabetes Atlas, 10th ed. Brussels: IDF; 2021. Available from: https://www.diabetesatlas.org
2. Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383(9922):1068–83.
3. Anjana RM, Pradeepa R, Das AK, et al. Physical activity and inactivity patterns in India — results from the ICMR-INDIAB study (Phase-1) [ICMR-INDIAB-5]. Int J Behav Nutr Phys Act. 2014;11:26.
4. DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773–95.
5. Ferrannini E, DeFronzo RA. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J. 2015;36(34):2288–96.
6. American Diabetes Association Professional Practice Committee. Standards of Medical Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S1–S321.
7. Lipska KJ, Parker MM, Moffet HH, Huang ES, Karter AJ. Association of initiation of basal insulin analogs vs neutral protamine Hagedorn insulin with hypoglycaemia-related emergency department visits or hospital admissions and with glycaemic control in patients with type 2 diabetes. JAMA. 2018;320(1):53–62.
8. Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370–80.
9. Foretz M, Guigas B, Viollet B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nat Rev Endocrinol. 2019;15(10):569–89.
10. Sola D, Rossi L, Schianca GP, et al. Sulfonylureas and their use in clinical practice. Arch Med Sci. 2015;11(4):840–8.
11. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise. Diabetes Care. 2010;33(10):2217–24.
12. Deacon CF. Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes. Front Endocrinol (Lausanne). 2019;10:80.
13. Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.
14. Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Steering Committee. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.
15. Perkovic V, Jardine MJ, Neal B, et al.; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306.
16. McMurray JJV, Solomon SD, Inzucchi SE, et al.; DAPA-HF Trial Committees. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.
17. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–86.
18. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Diabetes Care. 2015;38(1):140–9.
19. Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35(11):1763–74.
20. Home PD, Pocock SJ, Beck-Nielsen H, et al.; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD). Lancet. 2009;373(9681):2125–35.
21. Scheen AJ. Pharmacokinetic and pharmacodynamic interactions between antidiabetic drugs and other common medications. Curr Drug Metab. 2015;16(8):662–78.
22. Chisholm-Burns MA, Kim Lee J, Spivey CA, et al. US pharmacists' effect as team members on patient care: systematic review and meta-analyses. Med Care. 2010;48(10):923–33.
23. Santschi V, Chiolero A, Colosimo AL, et al. Improving blood pressure control through pharmacist interventions: a meta-analysis of randomized controlled trials. J Am Heart Assoc. 2014;3(2):e000718.
24. Frias JP, Davies MJ, Rosenstock J, et al.; SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–15.
25. Husain M, Birkenfeld AL, Donsmark M, et al.; PIONEER 6 Investigators. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841–51.
26. Jastreboff AM, Aronne LJ, Ahmad NN, et al.; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–16.
27. Bhatt DL, Szarek M, Steg PG, et al.; SOLOIST-WHF Trial Investigators. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117–28.

28. Brown SA, Kovatchev BP, Raghinaru D, et al.; iDCL Trial Research Group. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med. 2019;381(18):1707–17.
29. Gregg EW, Sattar N, Ali MK. The changing face of diabetes complications. Lancet Diabetes Endocrinol. 2016;4(6):537–47.
30. Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes. Diabetes Care. 2013;36(11):3411–7.
31. Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010;340:b4909.
32. Pratley RE, Aroda VR, Lingvay I, et al.; SUSTAIN 7 Investigators. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275–86.